Feasibility study of Californium-252 for the therapy of stage IV cervical cancer

Journal Article · Wed Jun 15 04:00:00 EDT 1988 · Cancer (Philadelphia); (United States)

DOI:https://doi.org/10.1002/1097-0142(19880615)61:12<2448::AID-CNCR2820611210>3.0.CO;2-E· OSTI ID:7152979

Maruyama, Y; Van Nagell, Jr, J R; Yoneda, J; Donaldson, E; Gallion, H; Patel, P; Kryscio, R J

Twenty patients with Stage IVA and IVB cervic cancers were treated with Californium-252 (Cf) neutron brachytherapy (NT) in a feasibility trial between 1976 and 1986. Eleven patients had Stage IVA disease; nine patients had Stage IVB disease. Patient compliance with therapy was poor in four of nine patients with Stage IVB disease, and the 50% survival time was 6 months. In Stage IVA disease there were 18% 3-year survivals. For those that failed, the 50% survival time was 7.5 months. Because of the frequency of disseminated metastases, effective adjuvant therapy needs to be developed to use after the tumor debulking therapy, especially for Stage IVB disease. A single early Cf-NT implant followed by 6000 cGy of whole-pelvis fractionated radiation would accomplish this adequately for local tumor control and palliation.

• Research Organization: Univ. of Kentucky Medical Center, Lexington (USA)
• OSTI ID: 7152979
• Journal Information: Cancer (Philadelphia); (United States), Journal Name: Cancer (Philadelphia); (United States) Vol. 61:12; ISSN CANCA
• Country of Publication: United States
• Language: English

Related Subjects

550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ACTINIDE ISOTOPES
ACTINIDE NUCLEI
ALPHA DECAY RADIOISOTOPES
BODY
CALIFORNIUM 252
CALIFORNIUM ISOTOPES
DISEASES
EVEN-EVEN NUCLEI
FEASIBILITY STUDIES
FEMALE GENITALS
HEAVY NUCLEI
IMPLANTS
ISOTOPES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ORGANS
PATIENTS
RADIATION SOURCE IMPLANTS
RADIATION SOURCES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SURVIVAL CURVES
THERAPEUTIC USES
THERAPY
USES
UTERUS
YEARS LIVING RADIOISOTOPES